Category icon
The New Era in AF Screening at Home

Prof Dr Gregory YH Lip, Prof Dr med Bernd Sanner, Assoc Prof Keitaroo Senoo

Category icon
The Christmas Lecture: A Celebration of Cardiovascular Nursing

Yvonne Millerick, Jayne Masters, Charlie Bloe et al

Category icon
Heart Failure With Mid-range or Recovered Ejection Fraction: Differential…

Davide Margonato, Simone Mazzetti, Renata De Maria, et al

Category icon
Transcriptomic Research in Heart Failure with Preserved Ejection Fraction:…

Sebastian Rosch, Karl-Philipp Rommel, Markus Scholz, et al

Category icon
Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart…

Sebastiaan HC Klaassen, Dirk J van Veldhuisen, Hans LA Nienhuis, et al

Category icon
Treating Mitral Regurgitation in the Wake of COAPT

Kelly H Schlendorf, Jared O’Leary, JoAnn Lindenfeld,

Category icon
Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use

Zoltán Papp, Piergiuseppe Agostoni, Julian Alvarez, et al

Category icon
Telemedicine, Artificial Intelligence and Humanisation of Clinical…

Domenico D’Amario, Francesco Canonico, Daniele Rodolico, et al

Category icon
Ticagrelor Monotherapy Versus Ticagrelor Plus Aspirin

Johny Nicolas, Usman Baber, Roxana Mehran,

Category icon
Contemporary Management of Secondary Mitral Regurgitation

Kashish Goel, Colin M Barker, JoAnn Lindenfeld,

About

Heart failure (HF) is a rapidly growing public health issue with an estimated prevalence of >37.7 million individuals globally. HF is a shared chronic phase of cardiac functional impairment secondary to many aetiologies, and patients with HF experience a range of symptoms that affect their quality of life, including dyspnoea, fatigue, poor exercise tolerance and fluid retention.

The burden of HF will continue to rise, due to population aging, population growth and improved treatment of HF and other cardiovascular disorders. As a result, clinicians will be increasingly challenged to develop treatment plans and care systems that reduce the high levels of morbidity and mortality experienced by these patients, both from their HF and other comorbidities.

Related Articles

Articles

Heart Failure With Mid-range or Recovered Ejection Fraction: Differential…

Davide Margonato, Simone Mazzetti, Renata De Maria,

Citation: Cardiac Failure Review 2020;6:e28.

Transcriptomic Research in Heart Failure with Preserved Ejection Fraction:…

Sebastian Rosch, Karl-Philipp Rommel, Markus Scholz,

Citation: Cardiac Failure Review 2020;6:e24.

Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart…

Sebastiaan HC Klaassen, Dirk J van Veldhuisen, Hans LA Nienhuis,

Citation: Cardiac Failure Review 2020;6:e21.

Morphine in the Setting of Acute Heart Failure: Do the Risks Outweigh the…

Oren Caspi, Doron Aronson,

Citation: Cardiac Failure Review 2020;6:e20.